(Q33270016)

English

Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

4 references

7 November 2019

13 November 2019

18 November 2019

18 September 2020

Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review (English)

1 reference

Europe PubMed Central

24 July 2017

1 reference

7 November 2019

polycyclic compound

1 reference

13 November 2019

1 reference

18 November 2019

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

1 reference

18 September 2020

systematic review

1 reference

based on heuristic

inferred from title

object named as

J Picot

2

0 references

author name string

J Bryant

1

1 reference

Europe PubMed Central

24 July 2017

L Baxter

3

1 reference

Europe PubMed Central

24 July 2017

G Levitt

4

1 reference

Europe PubMed Central

24 July 2017

I Sullivan

5

1 reference

Europe PubMed Central

24 July 2017

A Clegg

6

1 reference

Europe PubMed Central

24 July 2017

language of work or name

0 references

publication date

1 January 2007

1 reference

Europe PubMed Central

24 July 2017

29 January 2007

4 references

7 November 2019

13 November 2019

18 November 2019

18 September 2020

British Journal of Cancer

5 references

Europe PubMed Central

24 July 2017

7 November 2019

13 November 2019

18 November 2019

18 September 2020

96

1 reference

Europe PubMed Central

24 July 2017

226-230

1 reference

Europe PubMed Central

24 July 2017

2

1 reference

Europe PubMed Central

24 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603562

0 references

Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

Caring for survivors of childhood cancers: the size of the problem

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

Cardioprotective interventions for cancer patients receiving anthracyclines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

The role of iron in doxorubicin-induced cardiomyopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

Early identification of anthracycline cardiomyopathy: possibilities and implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

Cardiac toxicity of daunorubicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

14 July 2018

Does anthracycline administration by infusion in children affect late cardiotoxicity?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603562

21 January 2018

Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603562

21 January 2018

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360000

31 October 2018

Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242696

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603562

1 reference

Europe PubMed Central

24 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33270016&oldid=1500125260"